MicroRNA-195-3p inhibits cyclin dependent kinase 1 to induce radiosensitivity in nasopharyngeal carcinoma

References

• Chen YP, Chan ATC, Le QT, et al. Nasopharyngeal carcinoma. Lancet. 2019 Jul 6;394(10192):64–80.
   PubMed Web of Science ®Google Scholar
• Bossi P, Chan AT, Licitra L, et al. Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up(†). Ann Oncol. 2021 Apr;32(4):452–465.
   PubMed Web of Science ®Google Scholar
• Guan S, Wei J, Huang L, et al. Chemotherapy and chemo-resistance in nasopharyngeal carcinoma. Eur J Med Chem. 2020 Dec 1;207:112758.
   PubMed Web of Science ®Google Scholar
• Lv J, Chen Y, Zhou G, et al. Liquid biopsy tracking during sequential chemo-radiotherapy identifies distinct prognostic phenotypes in nasopharyngeal carcinoma. Nat Commun. 2019 Sep 2;10(1):3941.
   PubMedGoogle Scholar
• Saliminejad K, Khorram Khorshid HR, Soleymani Fard S, et al. An overview of microRNAs: biology, functions, therapeutics, and analysis methods. J Cell Physiol. 2019 May;234(5):5451–5465.
   PubMed Web of Science ®Google Scholar
• Ambros V. The functions of animal microRNAs. Nature. 2004 Sep 16;431(7006):350–355.
   PubMed Web of Science ®Google Scholar
• Di Leva G, Garofalo M, Croce CM. MicroRNAs in cancer. Annu Rev Pathol. 2014;9:287–314.
   PubMed Web of Science ®Google Scholar
• Lien MY, Tsai HC, Chang AC, et al. Chemokine CCL4 induces vascular endothelial growth factor C expression and Lymphangiogenesis by miR-195-3p in oral squamous cell carcinoma. Front Immunol. 2018;9:412.
   PubMed Web of Science ®Google Scholar
• Yang H, Gao S, Chen J, et al. UBE2I promotes metastasis and correlates with poor prognosis in hepatocellular carcinoma. Cancer Cell Int. 2020;20:234.
   PubMed Web of Science ®Google Scholar
• Tian Y, Yan M, Zheng J, et al. miR-483-5p decreases the radiosensitivity of nasopharyngeal carcinoma cells by targeting DAPK1. Lab Invest. 2019 May;99(5):602–611.
   PubMed Web of Science ®Google Scholar
• Wang T, Dong XM, Zhang FL, et al. miR-206 enhances nasopharyngeal carcinoma radiosensitivity by targeting IGF1. Kaohsiung J Med Sci. 2017 Sep;33(9):427–432.
   PubMed Web of Science ®Google Scholar
• Kang M, Xiao J, Wang J, et al. MiR-24 enhances radiosensitivity in nasopharyngeal carcinoma by targeting SP1. Cancer Med. 2016 Jun;5(6):1163–1173.
   PubMed Web of Science ®Google Scholar
• Ho JH. Nasopharyngeal carcinoma (NPC). Adv Cancer Res. 1972;15:57–92.
   PubMedGoogle Scholar
• Allen C, Her S, Jaffray DA. Radiotherapy for cancer: present and future. Adv Drug Deliv Rev. 2017 Jan 15;109:1–2.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chen L, Hu GQ, et al. Gemcitabine and Cisplatin induction chemotherapy in Nasopharyngeal Carcinoma. N Engl J Med. 2019 Sep 19;381(12):1124–1135.
   PubMed Web of Science ®Google Scholar
• Tang LQ, Chen DP, Guo L, et al. Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol. 2018 Apr;19(4):461–473.
   PubMed Web of Science ®Google Scholar
• Schäfer P. microRNAs - Game-changers in plant symbioses. J Plant Physiol. 2021;263:153459.
   PubMed Web of Science ®Google Scholar
• Liu H, Chen C, Zeng J, et al. MicroRNA-210-3p is transcriptionally upregulated by hypoxia induction and thus promoting EMT and chemoresistance in glioma cells. PloS One. 2021;16(7):e0253522.
   PubMed Web of Science ®Google Scholar
• Wang S, Pan Y, Zhang R, et al. Hsa-miR-24-3p increases nasopharyngeal carcinoma radiosensitivity by targeting both the 3ʹUTR and 5ʹUTR of Jab1/CSN5. Oncogene. 2016 Nov 24;35(47):6096–6108.
   PubMed Web of Science ®Google Scholar
• Liu W, Chen H, Wang D. Protective role of astragaloside IV in gastric cancer through regulation of microRNA-195-5p-mediated PD-L1. Immunopharmacol Immunotoxicol. 2021 Aug; 43(4): 443-451.
   Web of Science ®Google Scholar
• Chen J, Gao C, Zhu W. Long non-coding RNA SLC25A25-AS1 exhibits oncogenic roles in non-small cell lung cancer by regulating the microRNA-195-5p/ITGA2 axis. Oncol Lett. 2021;22(1):529.
   PubMed Web of Science ®Google Scholar
• Chen S, Wang L, Yao X, et al. miR-195-5p is critical in REGγ-mediated regulation of wnt/β-catenin pathway in renal cell carcinoma. Oncotarget. 2017 Sep 8;8(38):63986–64000.
   PubMedGoogle Scholar
• Jin L, Li X, Li Y, et al. Identification of miR‑195‑3p as an oncogene in RCC. Mol Med Rep. 2017 Apr;15(4):1916–1924.
   PubMed Web of Science ®Google Scholar
• Jin M, Wang L, Zheng T, et al. MiR-195-3p inhibits cell proliferation in cervical cancer by targeting BCDIN3D. J Reprod Immunol. 2021 Feb;143:103211.
   PubMed Web of Science ®Google Scholar
• Gavet O, Pines J. Progressive activation of CyclinB1-Cdk1 coordinates entry to mitosis. Dev Cell. 2010 Apr 20;18(4):533–543.
   PubMed Web of Science ®Google Scholar
• Haneke K, Schott J, Lindner D, et al. CDK1 couples proliferation with protein synthesis. J Cell Biol. 2020 Mar 2;219(3). DOI:10.1083/jcb.201906147.
   PubMed Web of Science ®Google Scholar
• Xie B, Wang S, Jiang N, et al. Cyclin B1/CDK1-regulated mitochondrial bioenergetics in cell cycle progression and tumor resistance. Cancer Lett. 2019 Feb 28;443:56–66.
   PubMed Web of Science ®Google Scholar
• Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009 Mar;9(3):153–166.
   PubMed Web of Science ®Google Scholar
• Luo X, He X, Liu X, et al. miR-96-5p suppresses the progression of Nasopharyngeal Carcinoma by targeting CDK1. Onco Targets Ther. 2020;13:7467–7477.
   PubMed Web of Science ®Google Scholar
• Izadi S, Nikkhoo A, Hojjat-Farsangi M, et al. CDK1 in breast cancer: implications for theranostic potential. Anticancer Agents Med Chem. 2020;20(7):758–767.
   PubMed Web of Science ®Google Scholar
• Zhang P, Kawakami H, Liu W, et al. Targeting CDK1 and MEK/ERK overcomes apoptotic resistance in BRAF-mutant human colorectal cancer. Mol Cancer Res. 2018 Mar;16(3):378–389.
   PubMed Web of Science ®Google Scholar
• Qian JY, Gao J, Sun X, et al. KIAA1429 acts as an oncogenic factor in breast cancer by regulating CDK1 in an N6-methyladenosine-independent manner. Oncogene. 2019 Aug;38(33):6123–6141.
   PubMed Web of Science ®Google Scholar
• Wang J, Chang L, Lai X, et al. Tetrandrine enhances radiosensitivity through the CDC25C/CDK1/cyclin B1 pathway in nasopharyngeal carcinoma cells. Cell Cycle. 2018;17(6):671–680.
   PubMed Web of Science ®Google Scholar